Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

Bibliographic Details
Main Authors:	Bois A du, Moiseenko V, Biakhov M, Eiermann W, Ströhlein M, Makhson A, Lichinitser M, Pfisterer J, Schmalfeldt B, Sommer H, Gorbounova V, Burges A, Wimberger P, Kimmig R
Format:	Article
Language:	English
Published:	BMC 2004-07-01
Series:	Cancer Cell International

Similar Items